Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin

2021 ◽  
Author(s):  
Tuan Vu ◽  
Natalie Anthony ◽  
Raul Alsina ◽  
Brittany Harvey ◽  
Allison Schleutker ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Intravenous Immunoglobulin ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Demyelinating Polyneuropathy ◽  
Subcutaneous Immunoglobulin ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Previously Treated

scholarly journals Subcutaneous immunoglobulin proves to be an effective alternative to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyneuropathy

2020 ◽  
Vol 6 (2) ◽  
Author(s):  
Benjamin Ross
Keyword(s):  
Intravenous Immunoglobulin ◽  
Maintenance Treatment ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Clinical Decision ◽  
Demyelinating Polyneuropathy ◽  
Subcutaneous Immunoglobulin ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inflammatory Demyelinating Polyneuropathy

A clinical decision report appraising van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46. https://doi.org/10.1016/S1474-4422(17)30378-2

scholarly journals Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints

2014 ◽  
Vol 72 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Patricia Leila dos Santos ◽  
Graziela A. Nogueira de Almeida-Ribeiro ◽  
Daniele Miguel Daoud Silva ◽  
Wilson Marques Junior ◽  
Amilton Antunes Barreira
Keyword(s):  
Quality Of Life ◽  
Mental State ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Short Form ◽  
Demyelinating Polyneuropathy ◽  
Functional Impairments ◽  
Health States ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Sociodemographic Profile

Whereas an evaluation of quality of life and possible impacts on the mental state of a patient may help to evaluate the evolution of chronic inflammatory demyelinating polyneuropathy (CIDP), the aim of this study was to study the psychological profile of patients, and evaluate quality of life associated with the disease. Method 41 patients were evaluated using a Mini-Mental State Examination (MMSE) and a Short-Form Health Survey (SF-36). Results The mean age of the patients was 50.6 years, 63.4% men. Of the participants, 65.9% had other health problems, 39% reported needing help with activities of daily living, 49% slept less than 8 hours per night, and 34.1% complained of some memory deficit. The average MMSE score was 26. Impairment of functional capacity and pain were the more important altered health states. Conclusion CIDP has important social and economic impacts, owing to functional impairments that can lead to professional and personal limitations.

Sign in / Sign up

Export Citation Format

Share Document